Effects of olprinone on hepatosplanchnic circulation and mitochondrial oxidation in a porcine model of endotoxemia

Kuniyoshi, Tamotsu; Kakihana, Yasuyuki; Isowaki, Sumikazu; Nagata, Emi; Tobo, Kazumi; Kaminosono, Tatsuya; Hashiguchi, Tetsuaki; Tahara, Masamichi; Kawamae, Hirokazu; Okayama, Naoko; Kanmura, Yuichi

doi:10.1007/s00540-005-0340-2

Cited by 7 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 It has been reported that olprinone showed antiinfl ammatory eff ects in experimental models of myocardial ischemia-reperfusion injury, 30 lipopolysaccharide-induced lung injury, 31 ischemiareperfusion-induced acute renal injury, 16 and endotoxic shock. 32 In the present study, patients in the olprinone group showed signifi cantly lower WBC counts and CRP levels aft er surgery compared with the placebo group.…”

Section: Discussionmentioning

confidence: 91%

A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer

Nojiri

Yamamoto

Maeda

et al. 2015

Chest

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 91%

A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer

Nojiri

Yamamoto

Maeda

et al. 2015

Chest

View full text Add to dashboard Cite

“…Olprinone induces relaxation of RGEA and internal thoracic artery [8] and decreases the rhythmical contraction of the RGEA as effectively as diltiazem [9]. Olprinone also enhances hepatosplanchnic blood flow and increases hepatic oxygen delivery [10,11], which might be advantageous during liver transplantation.…”

Section: Discussionmentioning

confidence: 99%

Anesthetic management of a patient undergoing liver transplantation who had previous coronary artery bypass grafting using an in situ right gastroepiploic artery

2010

View full text Add to dashboard Cite

We describe successful anesthetic management during living-donor liver transplantation in a 63-year-old man with previous coronary artery bypass grafting that employed an in situ right gastroepiploic artery (RGEA). Anesthesia was maintained with 1.5% isoflurane in air/oxygen and fentanyl. A 5-lead electrocardiogram, transesophageal echocardiogram, and pacing pulmonary artery catheter evaluated cardiac function. A pacing wire was inserted through the catheter to prepare for intraoperative severe bradyarrhythmia. Olprinone and nicorandil were continuously infused to prevent the decrease in coronary arterial blood flow and the collapse of cardiac function.Avoiding disruption of circulation to coronary arteries through injury or spasm of the RGEA graft and preparing for the cardiac insufficiency during liver transplantation of a patient with previous coronary artery bypass grafting using an in situ RGEA is critical.3

show abstract

“…In a porcine model of endotoxemia, endotoxin decreased the cardiac index and hepatic oxygen delivery (DO2H), while oxygen consumption (VO2H) was unchanged. Treatment with PDE3 inhibitor olprinone unchanged cardiac index, but elevated DO2H and VO2H indicating a restoration of hepatic circulation, and prevented LPS-induced reduction of cytochrome aa3 and increase in arterial lactate values [135] (Table 4). Vasodilating effects of olprinone on peripheral and pulmonary vessels in hypoxic conditions were shown in a canine model of hypoxic pulmonary hypertension where intravenous olprinone increased heart rate and decreased mean aortic pressure, mean pulmonary arterial pressure, pulmonary vascular resistance, systemic vascular resistance, and right ventricular stroke work index, without the change in cardiac index [136].…”

Section: Pde3 Inhibitorsmentioning

confidence: 96%

Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?

Mokrá

Mokrý

2021

IJMS

View full text Add to dashboard Cite

Despite progress in understanding the pathophysiology of acute lung damage, currently approved treatment possibilities are limited to lung-protective ventilation, prone positioning, and supportive interventions. Various pharmacological approaches have also been tested, with neuromuscular blockers and corticosteroids considered as the most promising. However, inhibitors of phosphodiesterases (PDEs) also exert a broad spectrum of favorable effects potentially beneficial in acute lung damage. This article reviews pharmacological action and therapeutical potential of nonselective and selective PDE inhibitors and summarizes the results from available studies focused on the use of PDE inhibitors in animal models and clinical studies, including their adverse effects. The data suggest that xanthines as representatives of nonselective PDE inhibitors may reduce acute lung damage, and decrease mortality and length of hospital stay. Various (selective) PDE3, PDE4, and PDE5 inhibitors have also demonstrated stabilization of the pulmonary epithelial–endothelial barrier and reduction the sepsis- and inflammation-increased microvascular permeability, and suppression of the production of inflammatory mediators, which finally resulted in improved oxygenation and ventilatory parameters. However, the current lack of sufficient clinical evidence limits their recommendation for a broader use. A separate chapter focuses on involvement of cyclic adenosine monophosphate (cAMP) and PDE-related changes in its metabolism in association with coronavirus disease 2019 (COVID-19). The chapter illuminates perspectives of the use of PDE inhibitors as an add-on treatment based on actual experimental and clinical trials with preliminary data suggesting their potential benefit.

show abstract

Effects of olprinone on hepatosplanchnic circulation and mitochondrial oxidation in a porcine model of endotoxemia

Abstract: Our data for this porcine endotoxemia model suggest that olprinone may have beneficial therapeutic effects in restoring not only systemic and hepatic circulation but also mitochondrial oxidation in the liver.

Cited by 7 publications

References 16 publications

A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer

A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer

Anesthetic management of a patient undergoing liver transplantation who had previous coronary artery bypass grafting using an in situ right gastroepiploic artery

Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?

Contact Info

Product

Resources

About